"Apolipoprotein A-V" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A minor apolipoprotein that associates with HIGH-DENSITY LIPOPROTEINS (HDL), VERY-LOW-DENSITY LIPOPROTEINS (VLDL), and CHYLOMICRONS. It regulates levels of plasma TRIGLYCERIDES by activating APOLIPOPROTEIN C-II LIPOPROTEIN LIPASE and inhibiting hepatic VLDL triglyceride hydrolysis.
| Descriptor ID |
D000072040
|
| MeSH Number(s) |
D10.532.091.200.575 D12.776.070.400.200.575 D12.776.521.120.200.575
|
| Concept/Terms |
Apolipoprotein A-V- Apolipoprotein A-V
- Apolipoprotein A V
- APOA5 Protein
- ApoA-V Protein
- ApoA V Protein
- Apo A-V Protein
- Apo A V Protein
- Apolipoprotein A5
- Apo A5 Protein
|
Below are MeSH descriptors whose meaning is more general than "Apolipoprotein A-V".
Below are MeSH descriptors whose meaning is more specific than "Apolipoprotein A-V".
This graph shows the total number of publications written about "Apolipoprotein A-V" by people in this website by year, and whether "Apolipoprotein A-V" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2004 | 0 | 1 | 1 |
| 2006 | 0 | 3 | 3 |
| 2011 | 0 | 2 | 2 |
| 2013 | 0 | 2 | 2 |
| 2014 | 0 | 1 | 1 |
| 2015 | 1 | 1 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Apolipoprotein A-V" by people in Profiles.
-
Apolipoprotein A-IV Inhibits AgRP/NPY Neurons and Activates Pro-Opiomelanocortin Neurons in the Arcuate Nucleus. Neuroendocrinology. 2016; 103(5):476-488.
-
Differential Lipid Response to Statins Is Associated With Variants in the BUD13-APOA5 Gene Region. J Cardiovasc Pharmacol. 2015 Aug; 66(2):183-8.
-
Exome sequencing identifies rare LDLR and APOA5 alleles conferring risk for myocardial infarction. Nature. 2015 Feb 05; 518(7537):102-6.
-
Rare APOA5 promoter variants associated with paradoxical HDL cholesterol decrease in response to fenofibric acid therapy. J Lipid Res. 2013 Jul; 54(7):1980-7.
-
Trans-ethnic fine-mapping of lipid loci identifies population-specific signals and allelic heterogeneity that increases the trait variance explained. PLoS Genet. 2013 Mar; 9(3):e1003379.
-
Variants in the APOA5 gene region and the response to combination therapy with statins and fenofibric acid in a randomized clinical trial of individuals with mixed dyslipidemia. Atherosclerosis. 2011 Dec; 219(2):737-42.
-
Association of gene variants with lipid levels in response to fenofibrate is influenced by metabolic syndrome status. Atherosclerosis. 2011 Apr; 215(2):435-9.
-
Longitudinal analysis of haplotypes and polymorphisms of the APOA5 and APOC3 genes associated with variation in serum triglyceride levels: the Bogalusa Heart Study. Metabolism. 2006 Dec; 55(12):1574-81.
-
Contrasting multi-site genotypic distributions among discordant quantitative phenotypes: the APOA1/C3/A4/A5 gene cluster and cardiovascular disease risk factors. Genet Epidemiol. 2006 Sep; 30(6):508-18.
-
Evidence for consistent intragenic and intergenic interactions between SNP effects in the APOA1/C3/A4/A5 gene cluster. Hum Hered. 2006; 61(2):87-96.